Loading search results
Sponsor study identifier
Secondary identifiers
OTHER_GRANT · Beijing Anzhen Hosptial, Capital Medical University
interventional
1,312
1 country
5
Study Start
March 17, 2026
Actual (reported)Primary Completion
June 1, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 1, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
This rigorously designed randomized controlled trial aims to investigate whether Magnetocardiography (MCG) can optimize the clinical pathway, improve quality of life, and reduce healthcare costs in patients with stable coronary artery disease (SCAD) within real-world clinical settings, thereby generating evidence for the future application of MCG in clinical decision-making pathways. Stable CAD patients with at least one major coronary vessel showing 50%-90% stenosis on coronary CTA will be enrolled based on predefined criteria. Stratified by study center and using a central web-based randomization system, participants will be allocated in a 1:1 ratio to either the \*\*MCG-guided group\*\* (where treatment recommendations for invasive coronary angiography \[ICA\] or optimal medical therapy are based on MCG results) or the \*\*conventional management group\*\* (where treatment strategy is based on stenosis severity, pre-test probability, and functional test results). The study will proceed with the following evaluations:
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 1, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 6, 2026
Actual (reported)January 15, 2026
Actual (reported)March 17, 2026
Actual (reported)June 1, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
December 1, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Proportion of patients with non-obstructive coronary artery disease on invasive coronary angiography (ICA)
Compare the proportion of patients with non-obstructive coronary artery disease on planned invasive coronary angiography (ICA) performed within 90 days between the MCG-guided group and the conventional management group, where non-obstructive disease is defined as coronary stenosis \<70% or an invasive fractional flow reserve (FFR) value ≥0.8.
From randomization through day 90 after enrollment.
Seattle Angina Questionnaire (SAQ) Score
From randomization through month 12 after enrollment.
MACE
From randomization through month 12 after enrollment.
Healthcare Expenditure
From randomization through month 12 after enrollment.
Treatment strategies were recommended based on stenosis severity, pre-test probability, and functional test results: For patients with 50-70% stenosis, if the pre-test probability was \<15%, treatment recommendations had to be made by clinicians integrating one or more functional test results (e.g., exercise ECG, stress echocardiography, SPECT, stress CMR); if the pre-test probability was ≥15%, it was advised to recommend treatment strategies considering functional test results. For patients with CCTA-indicated 70-90% stenosis, clinicians could directly recommend ICA or optimal medical therapy.
Based on MCG results, either ICA or optimal medical therapy was recommended.
Based on MCG results, either ICA or optimal medical therapy was recommended.
Treatment strategy is recommended based on stenosis severity, pre-test probability, and results of functional tests.
Air Force Medical Center, People's Liberation Army of China
Beijing, Beijing Municipality, China
Beijing United Family Hospital
Beijing, Beijing Municipality, China
First Submitted
January 6, 2026
First Posted
January 15, 2026
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
首都医科大学附属北京安贞医院
Beijing, Beijing Municipality, China
The Third People's Hospital of Chengdu
Chengdu, Sichuan, China
Urumqi Friendship Hospital
Ürümqi, Xinjiang Uygur Autonomous Region, China
Study Start
March 17, 2026
Actual (reported)Primary Completion
June 1, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 1, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
April 2, 2026
Record last verified: 2026-04
The original database will be public one year after the end of the study by uploading the EXECL electronic database.
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: